These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 1732982)

  • 21. [Effects of biphasic spiral CT, conventional and iron oxide enhanced MRI on therapy and therapy costs in patients with focal liver lesions].
    Helmberger T; Gregor M; Holzknecht N; Rau H; Scheidler J; Reiser M
    Rofo; 2000 Mar; 172(3):251-9. PubMed ID: 10778456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers.
    Ma HL; Xu YF; Qi XR; Maitani Y; Nagai T
    Int J Pharm; 2008 Apr; 354(1-2):217-26. PubMed ID: 18191350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted contrast agents in MR imaging.
    Gupta H; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):171-84. PubMed ID: 8673713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of a stable cell culture assay for the functional assessment of novel MR contrast agents.
    Reimer P; Bader A; Weissleder R
    Eur Radiol; 1997; 7(4):527-31. PubMed ID: 9204333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography.
    Rappeport ED; Loft A
    Abdom Imaging; 2007; 32(5):624-34. PubMed ID: 17710359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.
    Rimola J; Forner A; Reig M; Vilana R; de Lope CR; Ayuso C; Bruix J
    Hepatology; 2009 Sep; 50(3):791-8. PubMed ID: 19610049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI Contrast Agents in Glycobiology.
    Geraldes CFGC; Peters JA
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma.
    Li Y; Chen Z; Li F; Wang J; Zhang Z
    Int J Nanomedicine; 2012; 7():4593-611. PubMed ID: 22956868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods.
    Rudin M; Rausch M; Stoeckli M
    Mol Imaging Biol; 2005; 7(1):5-13. PubMed ID: 15912270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New magnetic resonance imaging techniques for the detection of breast cancer.
    Orang-Khadivi K; Pierce BL; Ollom CM; Floyd LJ; Siegle RL; Williams RF
    Breast Cancer Res Treat; 1994; 32(1):119-35. PubMed ID: 7819581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MR imaging in the evaluation of hepatic metastases.
    Imam K; Bluemke DA
    Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):741-56. PubMed ID: 11149677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor-directed contrast agents for MR imaging: preclinical evaluation with affinity assays.
    Reimer P; Weissleder R; Wittenberg J; Brady TJ
    Radiology; 1992 Feb; 182(2):565-9. PubMed ID: 1732982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
    Weissleder R; Reimer P; Lee AS; Wittenberg J; Brady TJ
    AJR Am J Roentgenol; 1990 Dec; 155(6):1161-7. PubMed ID: 2122660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor imaging: application to MR imaging of liver cancer.
    Reimer P; Weissleder R; Lee AS; Wittenberg J; Brady TJ
    Radiology; 1990 Dec; 177(3):729-34. PubMed ID: 2243978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats.
    Leveille-Webster CR; Rogers J; Arias IM
    Hepatology; 1996 Jun; 23(6):1631-41. PubMed ID: 8675187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging.
    Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ
    Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.